目的探讨TACE联合3-DCRT治疗中晚期肝癌临床效果及应用价值。方法选取60例中晚期肝癌患者分为治疗组和对照组,分别接受TACE联合3-DCRT和单纯的TACE治疗,观察其有效率及生存期。结果所有患者均顺利完成相应的诊疗。治疗组的临床有效率86.7%,明显高于对照组的60%;远期疗效中治疗组的生存率明显高于对照组,生存时间也明显高于对照组。结论 TACE联合3-DCRT是治疗不能手术的原发性肝癌的有效方法,延长患者生存期,提高生存质量,值得我们在临床上推广。 Objective To investigate the clinical effect and application value of TACE combined with 3-DCRT in the treatment of advanced liver cancer. Methods Sixty patients with advanced hepatocellular carcinoma (HCC) were divided into treatment group and control group. TACE combined with 3-DCRT and TACE alone were used respectively to observe their efficiency and survival. Results All patients successfully completed the corresponding diagnosis and treatment. The clinical effective rate of the treatment group was 86.7%, which was significantly higher than that of the control group (60%). The survival rate of the treatment group was significantly higher than that of the control group and the survival time was significantly higher than that of the control group. Conclusion TACE combined with 3-DCRT is an effective method for the treatment of inoperable primary liver cancer, prolonging the survival of patients and improving the quality of life, which deserves our clinical promotion.